Spectroscopic and In Silico DNA Binding Studies on the Interaction of Some New N-Substituted Rhodanines with Calf-thymus DNA: In Vitro Anticancer Activities.
Animals
Antineoplastic Agents
/ chemical synthesis
Binding Sites
/ drug effects
Cattle
Cell Line, Tumor
Cell Proliferation
/ drug effects
DNA
/ drug effects
Dose-Response Relationship, Drug
Humans
Molecular Docking Simulation
Molecular Structure
Rhodanine
/ chemical synthesis
Structure-Activity Relationship
Anticancer activity
Calf-thymus DNA
Ct-DNA binding studies
N-substituted rhodanines
molecular docking
rhodanines.
Journal
Anti-cancer agents in medicinal chemistry
ISSN: 1875-5992
Titre abrégé: Anticancer Agents Med Chem
Pays: Netherlands
ID NLM: 101265649
Informations de publication
Date de publication:
2019
2019
Historique:
received:
07
02
2018
revised:
25
03
2018
accepted:
28
08
2018
pubmed:
3
10
2018
medline:
27
12
2019
entrez:
3
10
2018
Statut:
ppublish
Résumé
In this era of science, cancer is a black dot on the face of humankind. Consequently, the search of promising anticancer agents continues. Here we designed and synthesized new N-substituted rhodanines (RD1-7), evaluated their multispectroscopic interaction with calf thymus DNA, in silico and anticancer studies against MDA-MB-231cancer cell line. By MTT assay rhodanine RD1 was found to be the most potent with IC50 value of 72.61 μM. In addition, DNA binding studies (UV-vis and fluorescence) revealed strong binding affinity of RD1-7 with DNA (Kb in the range of 1.5-7.4 × 105 M-1). Moreover, molecular docking study, experimental DNA binding and anticancer studies are all well agreed to each other. It was observed that H-bonding and hydrophobic attractions were responsible for stability of DNAcompound adducts. Besides, the reported rhodanines (RD1-7) were found as minor groove binders of DNA. Concisely, RD1-7 indicated promising pharmacological properties and hence, shows auspicious future for the development of novel anticancer agents. The reported rhodanines showed excellent anticancer properties. Therefore, the described rhodanines may be used as potential anticancer agents in the future.
Sections du résumé
BACKGROUND
In this era of science, cancer is a black dot on the face of humankind. Consequently, the search of promising anticancer agents continues.
AIMS
Here we designed and synthesized new N-substituted rhodanines (RD1-7), evaluated their multispectroscopic interaction with calf thymus DNA, in silico and anticancer studies against MDA-MB-231cancer cell line.
METHODS
By MTT assay rhodanine RD1 was found to be the most potent with IC50 value of 72.61 μM. In addition, DNA binding studies (UV-vis and fluorescence) revealed strong binding affinity of RD1-7 with DNA (Kb in the range of 1.5-7.4 × 105 M-1). Moreover, molecular docking study, experimental DNA binding and anticancer studies are all well agreed to each other.
RESULTS
It was observed that H-bonding and hydrophobic attractions were responsible for stability of DNAcompound adducts. Besides, the reported rhodanines (RD1-7) were found as minor groove binders of DNA. Concisely, RD1-7 indicated promising pharmacological properties and hence, shows auspicious future for the development of novel anticancer agents.
CONCLUSION
The reported rhodanines showed excellent anticancer properties. Therefore, the described rhodanines may be used as potential anticancer agents in the future.
Identifiants
pubmed: 30277166
pii: ACAMC-EPUB-93365
doi: 10.2174/1871520618666181002131125
doi:
Substances chimiques
Antineoplastic Agents
0
Rhodanine
7O50LKL2G8
DNA
9007-49-2
calf thymus DNA
91080-16-9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
425-433Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.